FDA Drug recall D-0042-2024
BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07…
- FDA Drug
- Class I
- completed
- Published 2023-10-18
On 2023-10-18 the FDA classified a Class I recall of BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07… by Scynexis, citing cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0042-2024 |
| Classification | Class I |
| Status | completed |
| Initiated | 2023-09-25 |
| Published | 2023-10-18 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Scynexis |
| Distribution | US |
Product
BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04
Reason
Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).
Identifiers
| code_info | Lot# LF21000008, Exp. 11/30/2023 Lot# LF22000051, Exp. 11/30/2025 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: completed.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0042-2024%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.